1 	|BT| (S (NP (NN Salinomycin)) (VP (VBZ induces) (NP (NN cell) (NN death)) (PP (IN via) (NP (NN inactivation) (NN Stat3) (NN downregulation) (NN Skp2))))) |ET| |BS|82:D12.644.360.024.342.300 85:G02.111.087.225 134:G04.299.139 507:D12.776.157.743|ES| 19:1 94:1 214:1 411:1 595:1 596:1 1314:1 1785:1 2646:1 5153:1

1 	|BT| (S (NP (NN Selenium) (NN treatment) (NN tumor) (NN promotion)) (VP (VBD increased) (S (NP (JJ hepatic) (NN GPx4) (NN expression)) (VP (VBN reduced) (NP (NN expression) (NN VEGF) (NN AP-1) (NN component) (NN c-fos)) (NP (ADJP (RB well) (JJ nodule)) (NN growth)))))) |ET| |BS|8:C04 45:G07.700.320.249 52:E02 935:D01.268.185.850 1418:D12.776.260.108.875|ES| 7:1 19:1 47:1 102:1 115:1 452:1 546:1 562:1 787:1 838:1 1021:1 2066:1 2337:1 4680:1 5155:1 5156:1 5157:1

1 	|BT| (S (NP (NNP Sesamin)) (ADVP (RB also)) (VP (VP (VBD potentiated) (SBAR (S (NP (NN tumor) (NN necrosis) (JJ factor-alpha-induced) (NN apoptosis)) (VP (VBD correlated) (SBAR (S (NP (NN suppression) (NN gene) (NN product)) (VP (VBN linked) (NP (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (, ,) (NP (NN Bcl-2) (NN survivin))) (-RRB- -RRB-))))))))) (, ,) (PRN (NP (NN proliferation) (-LRB- -LRB-) (FW e.g.) (, ,) (NP (NN cyclin) (NN D1))) (-RRB- -RRB-) (NP (, ,) (NP (NP (NN inflammation)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (, ,) (NP (NN cyclooxygenase-2))) (-RRB- -RRB-))) (, ,) (NP (NP (NN invasion)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (, ,) (NP (NN matrix) (NN metalloproteinase-9)) (, ,) (NP (JJ intercellular) (NN adhesion) (NN molecule) (CD 1))) (-RRB- -RRB-))) (, ,) (NP (NP (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (FW e.g.) (, ,) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor))) (-RRB- -RRB-))))))) |ET| |BS|6:G05.360.340.024.340 24:D08.811.600.720.750 39:G04.299.139.160 54:G05.360.340.024.340.375.500.791.150 108:G04.299.316 215:D12.644.360.262.150.100 371:A07.231 525:C23.550.470 586:D08.811.277.656.300.480.205.360 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1130:D12.644.276.390 1325:D12.776.395.550.200.450|ES| 2:1 5:1 7:1 9:1 10:1 14:1 19:1 61:1 89:1 94:1 98:1 102:1 158:1 180:1 185:1 274:1 299:1 446:1 620:1 675:1 743:1 744:1 753:1 1251:1 1363:1 1997:1 2157:1 2229:1 2453:1 2502:1 2952:1 3064:1 3092:1 3491:1 3679:1 4257:1 5158:1 5159:1

1 	|BT| (S (NP (NN SGE)) (VP (VBD inhibited) (NP (NP (NN induction) (JJ gamma-glutamyltranspeptidase-positive) (NNS hepatocytes)) (, ,) (NP (NN lipid) (NN peroxidation)) (, ,) (NP (NN gene) (NN expression) (NN Cyp1a1)) (, ,)) (VP (VBD caused) (NP (NN DC))))) |ET| |BS|122:C14.280.383 155:G05.355.310 262:A11.436.348 648:D08.811.913.050.200.500 1247:G02.111.087.520 1352:D08.244.453.040.332|ES| 2:1 9:1 19:1 115:1 365:1 736:1 894:1 2401:1 2506:1 4384:1 5160:1 5161:1 5162:1 5163:1

1 	|BT| (S (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (VP (VBD found) (NP (NN repressor) (NN Gadd45b) (NN gene) (NN binding) (JJ upstream) (JJ regulatory) (NN element)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 149:G05.360.340.024.340.364.875.890 209:G02.111.087.847 250:E07.305.812 1419:G02.111.570.080.689|ES| 9:1 10:1 14:1 19:1 37:1 251:1 487:1 860:1 861:1 862:1 1487:1 1817:1 1996:1 2960:1 4855:1 5070:1 5164:1

1 	|BT| (NP (NP (NP (NN Silencing) (NN CXCR4) (VBG impairing) (NN MIF-CXCR4) (NN signaling) (NN pathway) (NN ISO-1)) (, ,) (NP (NN pAb) (NN FL-115)) (, ,) (NP (NN AMD-3100)) (, ,) (NP (JJ monoclonal) (NN antibody) (NN 12G5)) (, ,) (NP (NN BIM-46187)) (VP (VBD abolished) (NP (JJ aggressive) (NN phenotype))))) |ET| |BS|80:G05.695 126:G02.111.087.800 162:F01.145.126.125 1204:D12.776.543.750.100.160.500.400 1420:D12.776.124.486.485.114.224 1421:D06.472.699.327.700.500|ES| 2:1 19:1 195:1 236:1 383:1 538:1 722:1 775:1 1365:1 2611:1 4220:1 4582:1 5165:1 5166:1 5167:1 5168:1 5169:1 5170:1 5171:1

1 	|BT| (S (NP (NN Silibinin)) (ADVP (RB strongly)) (VP (VBD increased) (SBAR (S (JJ phospho-extracellular) (NP (NP (NP (JJ signal-regulated) (NN kinase) (CD 1/2)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN Cip1/p21) (NN Kip1/p27)) (PRN (-LRB- -LRB-) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor)) (-RRB- -RRB-))) (NP (NN level))) (ADVP (RB moderately)) (VP (VBD decreased) (NP (NN Bcl-2) (NN survivin) (NN level))))))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 919:D08.811.913.696.620.682.700.567.249.500 1279:D12.644.360.225|ES| 2:1 10:1 14:1 19:1 47:1 158:1 202:1 249:1 380:1 470:1 635:1 1706:1 1707:1 2229:1 2531:1 4546:1 4592:1 4593:1 4594:1 4966:1 5172:1

1 	|BT| (S (PP (IN Since) (NP (NP (NN fate) (JJ chemotherapy-insensitive) (NN tumor) (NN cell)) (VP (ADVP (RB rarely)) (VBN described)))) (, ,) (NP (VBN performed) (NP (JJ comparative) (NN analysis) (NN 5-FU) (NN toxicity) (JJ p53-deficient) (NN cell))) (VP (VBP conclude) (NP (NP (NN p53) (NN act) (NN facilitator)) (NP (RB rather) (NN gatekeeper) (NN cell) (NN death))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 41:A11 81:E02.095.465.425.400.330.050.400 134:G04.299.139 151:E02.319 557:D02.241.081.069.600.150 560:D03.383.742.698.875.404|ES| 2:1 7:1 12:1 19:1 94:1 246:1 411:1 458:1 634:1 661:1 851:1 1968:1 2308:1 2406:1 2535:1 3001:1 4561:1 5173:1 5174:1 5175:1 5176:1 5177:1

1 	|BT| (S (NP (NN SiRNA) (NN treatment) (NN BNL-CL.2) (NN cell) (NN Tsc-22) (NNS oligonucleotides)) (SBAR (S (NP (JJ nonspecific) (NNS oligonucleotides)) (VP (VBD decreased) (NP (NN RNA) (NN protein) (NN expression) (NN Tsc-22)) (NP (CD 80-90) (NN %))))) (, ,) (NP (NP (NN expression) (NN Gadd45b) (NN gene)) (, ,) (NP (NN Lzts2)) (, ,)) (VP (VBD increased) (S (NP (NN time)) (NP (JJ initial) (NN decrease))))) |ET| |BS|7:D12.776 41:A11 52:E02 117:D13.150.650.700 155:G05.355.310 322:G01.910 1411:D13.695.578.424 1422:D13.444.735|ES| 2:1 4:1 9:1 19:1 47:1 94:1 115:1 202:1 295:1 369:1 515:1 546:1 1081:1 4161:1 4855:1 5178:1 5179:1 5180:1 5181:1 5182:1 5183:1 5184:1

1 	|BT| (S (NP (NP (NNP Sixth)) (, ,) (NP (NN curcumin))) (VP (VBD inhibited) (NP (NP (NN expression) (NN cell) (NN survival) (NN protein) (NN B-cell) (NN lymphoma-2)) (, ,) (NP (NN B-cell) (NN leukemia) (NN protein) (NN xL)) (, ,) (NP (NP (JJ X-linked) (NN inhibitor) (NN apoptosis) (NN protein)) (, ,) (NP (NN c-FLIP))) (, ,) (NP (NP (NP (JJ cellular) (NN inhibitor) (NN apoptosis) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN cIAP)) (-RRB- -RRB-))) (CD -1)) (, ,) (NP (NP (NN cIAP-2) (NN survivin) (NN protein)) (VP (VBN linked) (NP (NN cell) (NP (NN proliferation)) (, ,) (NP (NN cyclin) (NN D1)) (NP (NN c-Myc)))))))) |ET| |BS|7:D12.776 41:A11 108:G04.299.316 122:C14.280.383 183:G04.299.233.750 215:D12.644.360.262.150.100 692:D02.455.326.146.485.222.222 1423:D12.644.360.075.437.750 1424:C04.557.386.480.150 1425:C04.557.337.428.080.125 1426:C04.557.337.428.080|ES| 2:1 4:1 10:1 14:1 19:1 89:1 94:1 115:1 274:1 299:1 365:1 380:1 743:1 744:1 824:1 1363:1 2199:1 2229:1 2498:1 3074:1 5185:1 5186:1 5187:1 5188:1 5189:1 5190:1 5191:1 5192:1 5193:1

1 	|BT| (S (NP (NN SPARC) (NN promoter) (NN hypermethylation) (JJ colorectal) (NN cancer)) (VP (VBD reversed) (S (NP (NN 5-Aza-2) (`` `) (NN deoxycytidine) (NN increase) (NN SPARC) (NN expression)) (VP (VB improve) (NP (NN therapy) (NN response)))))) |ET| |BS|4:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 37:D12.776.157.125.715 52:E02 1427:D03.383.742.680.245.500 1428:D02.886.759.111|ES| 17:1 18:1 19:1 40:1 82:1 83:1 115:1 130:1 494:1 664:1 2466:1 4352:1 5194:1

1 	|BT| (S (NP (ADVP (RB Strikingly)) (, ,) (NP (NP (NN CYR61) (NN overexpression) (JJ impaired) (NN accumulation)) (NP (NP (JJ wild-type) (NN p53)) (PP (VBG following) (NP (NN Taxol) (NN exposure))))) (, ,) (NP (NN inhibition) (NN alphavbeta3) (NN ERK1/ERK2) (NN MAPK) (NN signaling))) (ADVP (RB completely)) (VP (VBD restored) (NP (JJ Taxol-induced) (NN upregulation) (NN p53)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 43:F01.145.544 69:G02.111.087.800 116:D08.811.913.696.620.682.700.567.249.750 249:G05.355.315.800 339:G02.111.087.880 919:D08.811.913.696.620.682.700.567.249.500 1429:D02.455.426.392.368.242.888.777|ES| 2:1 8:1 12:1 19:1 103:1 152:1 195:1 809:1 1126:1 1953:1 2003:1 2120:1 3244:1 3510:1 3792:1 4271:1 4893:1 5195:1 5196:1 5197:1 5198:1

1 	|BT| (S (NP (NP (JJ Subsequent) (NN inhibition) (NN Notch-1) (NN signaling) (NN sulfonamide) (NN GSI)) (PRN (-LRB- -LRB-) (NP (NN GSI34)) (-RRB- -RRB-))) (VP (VBD prevented) (SBAR (S (NP (NN induction) (NN NICD) (NN chemotherapy)) (VP (VBD blunted) (NP (NN Hes-1) (NN activation))))))) |ET| |BS|43:F01.145.544 69:G02.111.087.800 151:E02.319 1430:D02.065.884|ES| 10:1 14:1 19:1 20:1 103:1 195:1 225:1 495:1 736:1 1867:1 1944:1 2277:1 4269:1 4607:1 5199:1 5200:1 5201:1

1 	|BT| (S (NP (NN Sugiol)) (VP (VBD induced) (SBAR (S (NP (NN cell) (NN cycle) (NN arrest)) (VP (VBD decreased) (NP (NP (NP (NN expression) (NN level) (NN STAT3) (NN target) (NN gene)) (, ,) (NP (NN cyclin) (NN D1))) (, ,) (NP (NN cyclin) (NN A)) (, ,) (NP (NN survivin)))))))) |ET| |BS|82:D12.644.360.024.342.300 155:G05.355.310 215:D12.644.360.262.150.100 773:G04.299.134.109 1431:D12.644.360.262.100|ES| 2:1 9:1 19:1 69:1 94:1 115:1 160:1 202:1 249:1 251:1 412:1 601:1 602:1 743:1 744:1 2229:1 5202:1

1 	|BT| (S (NP (NP (NP (NN Sulindac) (NN cyclooxygenase-2) (NN inhibitor)) (, ,) (NP (NN etodolac)) (, ,)) (NN increase) (NN APC) (NN mRNA) (NN colon) (NN rat)) (VP (VBN treated) (NP (NN azoxymethane)))) |ET| |BS|3:C04.557.470.035.215.100 46:A03.556.124.526.356 52:E02 111:D13.444.735.544 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 251:D02.455.426.559.847.486.875 349:D27.505.519.389.310.500 683:D27.505.519.389.310 1317:D03.066.288.200|ES| 2:1 11:1 19:1 40:1 61:1 113:1 325:1 380:1 849:1 1099:1 1993:1 2965:1 4679:1

1 	|BT| (S (NP (NN TAM)) (VP (VBD increased) (NP (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (-LRB- -LRB-) (NN ERK) (-RRB- -RRB-) (NN phosphorylation)) (, ,) (NP (JJ related) (NN proliferation) (NN regeneration) (NN liver))) (VP (VBD decreased) (NP (NN DGAT2) (NN gene) (NN expression))))) |ET| |BS|155:G05.355.310 477:D08.811.913.696.620.682.700.567.249 478:D08.811.913.696.620.682.700.567 640:D02.455.426.559.389.150.700.900 925:G10.261.326.520 972:G02.111.087.677 1432:G02.111.570.060.040.750 1433:C05.651.575|ES| 2:1 9:1 10:1 14:1 19:1 47:1 115:1 202:1 299:1 419:1 470:1 836:1 1707:1 3260:1 3426:1 4812:1 5047:1 5203:1 5204:1

1 	|BT| (NP (DT The) (S (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (NN H-thymidine) (NN incorporation) (NN Western-blot) (NN assay)) (VP (VBD revealed) (SBAR (S (NP (NN cell) (NN proliferation)) (VP (VBD attenuated) (NP (NNP EGCG)) (PP (IN via) (NP (NP (NN upregulation) (NN BTG2) (NN expression)) (VP (VBG causing) (NP (NN cell) (NN cycle) (NN G1) (NN phase) (NN arrest) (NN OSCC) (NN cell))))))))))) |ET| |BS|41:A11 179:D01.248.497.300.459.700 183:G04.299.233.750 249:G05.355.315.800 255:E05.196.401.143 339:G02.111.087.880 1076:G04.299.134.109.249 1434:D03.383.742.680.705|ES| 10:1 14:1 19:1 94:1 115:1 275:1 299:1 310:1 596:1 601:1 602:1 670:1 691:1 808:1 862:1 1126:1 1491:1 2529:1 4885:1 4886:1 5087:1 5205:1 5206:1 5207:1

1 	|BT| (S (NP (DT The) (NN ability) (NN PF-03084014)) (VP (VBP inhibit) (NP (NP (NN gamma-secretase) (NN activity)) (VP (VBN shown) (NP (NP (NP (NN reduction) (JJ endogenous) (NN NICD) (NN level) (NN downregulation) (NN Notch) (NN target) (NN gene) (NN Hes-1) (NN cMyc) (NN T-cell) (JJ acute) (JJ lymphoblastic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN T-ALL)) (-RRB- -RRB-))) (NN cell) (NN line) (NN HPB-ALL)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 85:G02.111.087.225 122:C14.280.383 125:D08.811.277.656.300.032 385:F02.784.629.131 1435:C04.557.337.428.600.620|ES| 9:1 10:1 14:1 19:1 90:1 94:1 160:1 237:1 249:1 256:1 264:1 370:1 399:1 595:1 691:1 1300:1 1370:1 1866:1 2277:1 3870:1 5187:1 5200:1 5208:1 5209:1 5210:1 5211:1 5212:1 5213:1

1 	|BT| (S (NP (DT The) (NN activity) (NN PTEN)) (VP (VBD restored) (NP (VBN treated) (NN NF-kappaB) (NN inhibitor) (NN PDTC)))) |ET| |BS|52:E02 210:D12.776.260.600|ES| 19:1 380:1 399:1 691:1 714:1 1099:1 1936:1 4893:1 5214:1

1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP investigate) (NP (NP (NP (NN contribution) (CD 2) (NN source) (NN ROS)) (, ,) (NP (NP (NN cytochrome) (NN P450) (NN 2E1)) (PRN (-LRB- -LRB-) (NP (NN CYP2E1)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP NAD)) (PRN (-LRB- -LRB-) (NP (NN P)) (-RRB- -RRB-))) (NP (NP (NN H) (NN quinone) (NN oxidoreductase)) (PRN (-LRB- -LRB-) (NP (NN NQO1)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN alcohol) (NN modulation) (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NP (NN expression))) (, ,) (NP (NN splicing) (NN KLF6) (CD _) (NN V1) (NN KLF6) (CD _) (NN V2)) (, ,) (NP (NN effect) (NN TNFalpha) (, ,) (JJ downstream) (NN target))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 751:D02.033.375 789:D12.644.276.374.500.800 790:D12.644.276.374.750 822:D02.033 1218:D08.244.453.300 1436:G02.111.087.750.700|ES| 2:1 10:1 14:1 19:1 75:1 115:1 131:1 148:1 160:1 311:1 459:1 560:1 612:1 691:1 1360:1 1567:1 1945:1 2356:1 2549:1 3710:1 3788:1 4270:1 4635:1 4683:1 4684:1 4685:1 4752:1 5215:1 5216:1 5217:1 5218:1 5219:1 5220:1 5221:1

1 	|BT| (NP (NP (DT The) (NN aim) (NN study)) (VP (VBD determine) (S (NN correlation) (NN TS) (: -) (PRN (, ,) (NN TP) (: -)) (, ,) (NP (JJ DPD-gene) (NN expression) (NN response) (JJ 5-FU-based) (JJ long-term) (JJ pre-operative) (NN chemoradiotherapy)) (VP (VBN assessed) (NP (JJ histopathological) (NN tumour) (NN regression)))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 59:E02.186.079 154:Z01.058.266.887 155:G05.355.310 333:D01.045 560:D03.383.742.698.875.404 846:F01.393.784 1342:Z01.639.040 1437:C13.703.420.491.500|ES| 2:1 19:1 74:1 115:1 131:1 494:1 691:1 1011:1 1567:1 1988:1 1989:1 3002:1 3527:1 3544:1 3546:1 3823:1 4785:1 4787:1 4788:1 4789:1

1 	|BT| (S (NP (DT The) (JJ anti-MM) (NN activity) (NN PTC-209)) (VP (VBN accompanied) (NP (NP (JJ significant) (NN decrease) (NN cyclin) (NN D1)) (PRN (-LRB- -LRB-) (NP (NN CCND1)) (-RRB- -RRB-))) (S (NP (NN v-myc) (NP (NP (JJ avian) (NN myelocytomatosis) (JJ viral) (NN oncogene) (NN homolog)) (PRN (-LRB- -LRB-) (NP (NN MYC)) (-RRB- -RRB-))) (NN expression)) (ADVP (RB well)) (VP (NN upregulation) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN 1A)) (PRN (-LRB- -LRB-) (NP (NN CDKN1A)) (-RRB- -RRB-)) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN 1B)) (PRN (-LRB- -LRB-) (NP (NN CDKN1B)) (-RRB- -RRB-)))))) |ET| |BS|215:D12.644.360.262.150.100 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 1299:D12.644.360.225.500|ES| 10:1 14:1 19:1 24:1 115:1 135:1 295:1 380:1 399:1 470:1 472:1 691:1 743:1 744:1 787:1 1025:1 1126:1 2052:1 2801:1 3621:1 3969:1 4546:1 5100:1 5222:1 5223:1 5224:1 5225:1 5226:1 5227:1 5228:1

1 	|BT| (S (NP (DT The) (NN antitumor) (NN activity) (NN SRJ09)) (VP (VBD suggested) (VP (VBN mediated) (PP (IN via) (NP (NN induction) (NN p21) (NN expression) (NN suppression) (NN CDK-4) (NN expression))) (PP (IN without) (S (VP (VBG affecting) (NP (NP (NN cyclin) (NN D1) (NN trigger) (NN G1) (NN arrest)) (VP (VBG leading) (NP (NN apoptosis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 86:D01.268.556.435 215:D12.644.360.262.150.100 573:N05.715.350.200.650 978:D08.811.913.696.620.682.700.646.500|ES| 19:1 89:1 115:1 399:1 437:1 596:1 602:1 639:1 670:1 691:1 736:1 743:1 744:1 925:1 1135:1 1195:1 2015:1 2244:1 2453:1 2530:1 3763:1 5229:1

1 	|BT| (S (NP (DT The) (NN apoptosis)) (VP (VP (VBD induced) (NP (NP (NN PTX-2) (NN Hep3B) (NN cell)) (NP (NP (NP (VBN associated) (NN down-regulation) (JJ anti-apoptotic) (NN Bcl-2) (NN member)) (PRN (-LRB- -LRB-) (NP (NN Bcl-2) (NN Bcl-xL)) (-RRB- -RRB-))) (NP (NN IAP) (NN family) (NN protein))))) (, ,) (NP (NP (NP (NN up-regulation) (JJ pro-apoptotic) (NN Bax) (NN protein) (NN tumor) (NN necrosis) (JJ factor-related) (JJ apoptosis-inducing) (NN ligand)) (PRN (-LRB- -LRB-) (NP (NN TRAIL)) (-RRB- -RRB-))) (: -) (NP (NP (NP (NN receptor) (NN 1/receptor) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN DR4/DR5)) (-RRB- -RRB-))) (NP (JJ mitochondrial) (NN dysfunction)))))) |ET| |BS|39:G04.299.139.160 41:A11 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 142:I01.880.604 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 1272:D03.438.759.758.824.651.700 1438:D12.644.276.374.750.625 1439:D12.644.360.075.437|ES| 2:1 4:1 7:1 10:1 14:1 19:1 89:1 94:1 97:1 148:1 158:1 169:1 257:1 412:1 691:1 758:1 769:1 896:1 1695:1 1835:1 2004:1 4257:1 4502:1 4560:1 4630:1 4814:1 5230:1 5231:1 5232:1 5233:1 5234:1 5235:1 5236:1 5237:1

1 	|BT| (S (NP (DT The) (JJ apoptosis-inducing) (NN effect) (NN gastrin) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ relates) (NP (NP (VBN increased) (NP (NN IEX-1)) (NN expression)) (VP (VBG mediating) (NP (NP (NN NF-kappa) (NN B)) (NN inhibition)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 43:F01.145.544 199:D06.472.317.413 200:D06.472.317.413 210:D12.776.260.600|ES| 17:1 18:1 19:1 47:1 75:1 94:1 103:1 115:1 676:1 691:1 758:1 759:1 760:1 761:1 762:1 763:1

1 	|BT| (S (NP (NP (DT The) (NN AZD6244-doxorubicin)) (NP (NP (VBN combined) (NN protocol)) (VP (VBD promoted) (NP (NN apoptosis))))) (ADVP (RB also)) (VP (VBD induced) (NP (NP (JJ synergistic) (NN effect)) (VP (VBN seen) (NP (JJ single-agent-treated) (NN tumor)))) (, ,) (PP (VBG including) (NP (VBN increased) (NN expression) (NN p130) (NN RB) (NN tumor) (NN suppressor) (NN gene))))) |ET| |BS|8:C04 39:G04.299.139.160 52:E02 136:D02.455.426.559.847.562.050.200.175 155:G05.355.310 206:G05.360.340.024.340.375.249 213:F02.830.816.964 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725|ES| 2:1 5:1 7:1 9:1 19:1 47:1 75:1 89:1 115:1 164:1 412:1 561:1 691:1 700:1 724:1 1209:1 1912:1 2012:1 3216:1 5238:1 5239:1 5240:1

1 	|BT| (S (NP (DT The) (NN downregulation) (NN IRS1) (NN SOX9)) (ADVP (RB also)) (VP (VBD induced) (NP (NN sodium) (NN butyrate)))) |ET| |BS|85:G02.111.087.225 1075:D02.241.081.114.750|ES| 5:1 19:1 407:1 412:1 595:1 691:1 3758:1 5241:1 5242:1

1 	|BT| (S (NP (DT The) (JJ dual) (NN EGFR/HER2) (NN inhibitor) (NN lapatinib)) (ADVP (RB synergistically)) (VP (VBZ enhances) (NP (JJ antitumor) (NN activity) (NN histone) (NN deacetylase) (NN inhibitor) (NN panobinostat) (JJ colorectal) (NN cancer) (NN model)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 153:D27.505.519.389.360|ES| 17:1 18:1 19:1 72:1 380:1 399:1 503:1 504:1 691:1 1356:1 2067:1 2244:1 3347:1 3348:1 3349:1 5243:1

1 	|BT| (S (NP (DT The) (NN effect) (NN chloroform) (NN DCA) (JJ TCA-induced) (NN hypomethylation) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN kidney) (NN tumor)) (VP (VBD determined))) |ET| |BS|155:G05.355.310 242:A03.620 274:C04.588.945.947.535 1196:D02.455.526.439.224 1331:C06.198.439 1332:Z01.107.084.900|ES| 7:1 9:1 19:1 75:1 115:1 455:1 691:1 836:1 1582:1 1717:1 2337:1 4107:1 4179:1 4180:1 5244:1

1 	|BT| (S (NP (DT The) (NN expression) (NN HEF1)) (VP (VP (VBD upregulated) (NP (NN Wnt-3a) (, ,) (NN beta-catenin) (, ,) (NN Dvl2) (JJ dose-dependent) (NN manner))) (, ,) (VP (VBD suppressed) (PP (VBG following) (NP (NN beta-catenin) (NN downregulation) (NN shRNA)))))) |ET| |BS|23:D12.776.091.249 85:G02.111.087.225 1273:D13.150.650.700|ES| 2:1 19:1 60:1 115:1 125:1 307:1 595:1 691:1 974:1 1668:1 2824:1 3510:1 5029:1 5245:1 5246:1

1 	|BT| (S (NP (DT The) (NN expression) (NN Tsc-22)) (ADVP (RB also)) (VP (VBD repressed) (SBAR (S (NP (NN B6C3F1) (NN mouse) (NN liver) (NN tumor)) (VP (VBD induced) (NP (NP (JJ several) (NN chemical) (JJ 2-year) (NN carcinogenicity) (NN study)) (NP (ADJP (RB well) (JJ spontaneous)) (NN liver) (NN tumor)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 279:D27.888.569.100 515:C04.588.274.623|ES| 5:1 7:1 19:1 52:1 115:1 131:1 262:1 283:1 412:1 466:1 691:1 787:1 836:1 2124:1 3583:1 3986:1 4495:1 5180:1

1 	|BT| (S (NP (DT The) (NN inhibition) (NN NAG-1) (NN expression) (JJ small) (VBG interfering) (NN RNA)) (ADVP (RB significantly)) (VP (VBD blocked) (NP (NP (NP (JJ VES-induced) (NN poly)) (PRN (-LRB- -LRB-) (NP (NN ADP-ribose)) (-RRB- -RRB-))) (NN polymerase) (NN cleavage)) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN NAG-1)) (VP (MD may) (VP (VB play) (NP (NP (JJ important) (NN role)) (NP (JJ VES-induced) (NN apoptosis))))))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 39:G04.299.139.160 43:F01.145.544 79:I03.450.642.693 117:D13.150.650.700 470:C02.782.160.927 1248:D08.811.913.400.725.115.690 1440:G04.299.134.220.250|ES| 2:1 10:1 14:1 19:1 31:1 89:1 103:1 115:1 124:1 238:1 394:1 491:1 515:1 691:1 750:1 902:1 1009:1 1661:1 1662:1 2777:1 3019:1 4810:1 4811:1 5247:1

1 	|BT| (S (NP (DT The) (NN inhibition) (NN NF-kappaB) (NN activation)) (ADVP (RB thereby)) (VP (VBD led) (NP (NP (NN down-regulation) (NN gene) (NN product)) (VBN involved) (NP (NP (NN inflammation)) (PRN (-LRB- -LRB-) (NP (NN cyclooxygenase-2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN cyclin) (NN D1) (NN c-myc)) (-RRB- -RRB-))) (, ,) (NP (NP (NN invasion)) (PRN (-LRB- -LRB-) (NP (NN matrix) (NN metalloproteinase-9)) (-RRB- -RRB-))) (, ,) (NP (NP (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (-RRB- -RRB-))) (, ,) (NP (NP (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (NP (NN cIAP1)) (, ,) (NP (NN cIAP2)) (, ,) (NP (NP (JJ X-linked) (NN inhibitor) (NN apoptosis) (NN protein)) (, ,) (NP (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL))))) (-RRB- -RRB-)))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 43:F01.145.544 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 86:D01.268.556.435 108:G04.299.316 210:D12.776.260.600 215:D12.644.360.262.150.100 371:A07.231 525:C23.550.470 586:D08.811.277.656.300.480.205.360 1130:D12.644.276.390|ES| 2:1 4:1 9:1 10:1 14:1 19:1 61:1 89:1 94:1 102:1 103:1 158:1 185:1 225:1 257:1 274:1 299:1 380:1 455:1 620:1 675:1 691:1 714:1 743:1 744:1 774:1 1251:1 2157:1 2228:1 2502:1 3064:1 3092:1 3491:1 4814:1 4896:1 4980:1 5189:1 5248:1

1 	|BT| (S (S (NP (DT The) (JJ knockout) (NN animal)) (VP (VBD increased) (NP (NP (NN lipid) (NN peroxidation)) (VP (VBD enhanced) (NP (NN sensitivity) (JJ CCl4-induced) (NN liver) (NN damage)) (, ,) (PP (ADVP (RB largely)) (JJ due) (NP (NP (VBN increased) (NN CYP2E1) (NN expression) (NN diallyl) (NN sulfide)) (, ,) (NP (NN inhibitor) (NN CYP2E1)) (, ,))))))) (VP (VBD prevented) (NP (JJ CCl4-induced) (NN liver) (NN injury)))) |ET| |BS|12:Z01.542.049 19:B01.050 242:A03.620 1218:D08.244.453.300 1247:G02.111.087.520|ES| 2:1 19:1 46:1 47:1 71:1 115:1 380:1 385:1 607:1 691:1 836:1 1848:1 1944:1 2401:1 2416:1 2520:1 2595:1 2851:1 4270:1 4384:1 4385:1 4386:1

1 	|BT| (S (NP (DT The) (JJ objective) (NN study)) (VP (VBP examine) (NP (NP (NN effect) (JJ EGCG-induced) (NN BTG2) (NN expression) (JJ potential) (NN signal) (NN pathway)) (VP (VBN involved))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 415:F01.658.500 761:G02.111.087.800|ES| 19:1 75:1 115:1 131:1 383:1 691:1 774:1 827:1 859:1 960:1 2916:1 4886:1 5249:1

1 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ explores) (SBAR (S (NP (NP (NN effect) (JJ p53-modulating) (NN agent) (NN CP-31398)) (ADVP (RB alone))) (VP (VBN combined) (NP (NP (NP (NN celecoxib) (JJ azoxymethane-induced) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NN colon) (NN adenocarcinoma) (NN F344) (NN rat))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 46:A03.556.124.526.356 84:C04.557.470.200.025 132:D02.172.080 590:B01.050.050.199.520.760.200 684:D02.065.884.247 824:C04.834.020|ES| 10:1 14:1 19:1 75:1 113:1 131:1 164:1 241:1 255:1 691:1 728:1 849:1 1307:1 1431:1 1725:1 2533:1 2807:1 2913:1 2914:1 3047:1 3185:1 5250:1 5251:1

1 	|BT| (S (NP (NP (DT The) (NN Ras) (NN inhibitor) (JJ farnesylthiosalicyclic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FTS)) (-RRB- -RRB-))) (VP (VBZ prevents) (NP (NN nodule) (NN formation) (NN development) (JJ preneoplastic) (NN focus) (JJ altered) (NNS hepatocytes) (NN rat)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 20:G03.495 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 1062:D01.029|ES| 10:1 14:1 19:1 35:1 43:1 380:1 691:1 693:1 849:1 894:1 1275:1 1431:1 1438:1 1775:1 2718:1 4551:1 4680:1 5252:1

1 	|BT| (NP (NP (DT The) (NN Ras) (NN inhibitor) (NN S-trans)) (, ,) (NP (NP (NP (JJ trans-farnesylthiosalicylic) (NN acid) (NNS chemosensitizes)) (NP (JJ human) (NN tumor) (NN cell))) (PP (IN without) (S (VP (VBG causing) (NP (NN resistance))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 7:1 19:1 36:1 94:1 380:1 691:1 1094:1 1195:1 1275:1 1491:1 1775:1 4549:1 5253:1 5254:1

1 	|BT| (NP (NP (NP (DT The) (NN rate) (NN proliferation) (NN HT29) (JJ human) (NN colon) (NN cancer) (NN cell)) (SBAR (S (NP (VBN reduced) (JJ treated) (NN gamma-secretase) (NN inhibitor) (NN dibenzazepine)) (VP (VBP inhibit) (NP (NP (NN Notch) (NN signaling) (JJ small) (VBG interfering) (NN RNA)) (VP (VBD directed) (NP (NN Notch))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 117:D13.150.650.700 122:C14.280.383 125:D08.811.277.656.300.032 212:E01.370.225.500.385.500 792:A11.251.210.190.475|ES| 18:1 19:1 36:1 41:1 94:1 113:1 195:1 256:1 299:1 380:1 452:1 515:1 691:1 750:1 1099:1 1370:1 1866:1 3017:1 3018:1 3019:1 3020:1

1 	|BT| (S (NP (DT The) (ADJP (RB recently) (VBN completed)) (NN o-nitrotoluene) (NN study)) (VP (VBD provided) (SBAR (S (NP (JJ first) (JJ cecal) (NN tumor) (NN response) (NN opportunity)) (VP (VB evaluate) (NP (NP (NN morphology) (JJ molecular) (NN profile) (NN oncogene) (NN tumor) (NN suppressor) (NN gene) (JJ relevant)) (ADJP (JJ human)))))))) |ET| |BS|9:G05.360.340.024.340.375.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 206:G05.360.340.024.340.375.249 225:E05.337 1441:C04.588.274.476.411.184|ES| 7:1 9:1 19:1 24:1 36:1 131:1 161:1 348:1 494:1 691:1 700:1 772:1 816:1 865:1 890:1 1155:1 1711:1 4417:1 5255:1 5256:1 5257:1

1 	|BT| (NP (NP (DT The) (NN role) (NN p53) (NN mutation) (JJ anti-tumour) (NN response) (JJ selective) (NN COX-2) (NN inhibitor) (NN celecoxib) (JJ human) (NN glioblastoma) (NN cell) (NN unknown))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 15:F01.829.316.616 18:G05.365.590 41:A11 55:B01.050.150.900.649.801.400.112.400.400 349:D27.505.519.389.310.500 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247|ES| 12:1 19:1 31:1 34:1 36:1 76:1 94:1 380:1 494:1 691:1 1749:1 2182:1 2186:1 2434:1 2807:1

1 	|BT| (S (NP (DT The) (JJ tobacco-specific) (NN carcinogen) (NN NNK)) (VP (VBZ induces) (NP (NN DNA) (NN methyltransferase) (CD 1) (NN accumulation) (NN tumor) (NN suppressor) (NN gene) (NN hypermethylation) (NN mouse) (NN lung) (NN cancer) (NN patient)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 50:M01.643 206:G05.360.340.024.340.375.249 279:D27.888.569.100 459:B01.650.940.800.575.100.905.900 460:B01.650.940.800.575.100.905.900 462:J01.637.836 746:D08.811.150.240|ES| 7:1 9:1 18:1 19:1 52:1 98:1 120:1 214:1 328:1 664:1 666:1 691:1 700:1 2120:1 2125:1 2655:1 5258:1 5259:1

1 	|BT| (S (NP (NP (DT The) (NN tumor) (NN suppressor) (NN protein) (NN phosphatase) (NN tensin) (NN homologue)) (VP (VBN deleted) (S (NP (NP (NN chromosome) (CD ten)) (PRN (-LRB- -LRB-) (NP (NN PTEN)) (-RRB- -RRB-)))))) (VP (VBP play) (NP (NP (JJ important) (NN role)) (JJ intestinal) (NN cell) (NN proliferation) (NN differentiation) (NN tumor) (NN suppression)) (S (VP (VBG antagonizing) (NP (NN phosphatidylinositol) (NN 3-kinase)))))) |ET| |BS|8:C04 12:Z01.542.049 15:F01.829.316.616 47:A03.556.124 74:G04.299.151 79:I03.450.642.693 173:C07.465.864.500 183:G04.299.233.750 289:A11.284.187 1035:D08.811.277.352.650 1377:D08.811.913.696.620.500.100 1442:D12.776.624.776|ES| 4:1 7:1 10:1 14:1 19:1 31:1 94:1 109:1 215:1 226:1 238:1 299:1 574:1 691:1 700:1 902:1 1001:1 1005:1 1936:1 2453:1 3394:1 3619:1 3620:1 4969:1 5260:1

1 	|BT| (S (ADVP (RB Therefore)) (, ,) (VP (VBD investigated) (SBAR (IN whether) (S (NP (JJ lipogenic) (NN gene) (NN expression) (NN tumor) (NN cell)) (ADVP (RB differently)) (VP (VBD regulated) (NP (JJ omega-6) (NN omega-3) (NNS PUFAs))))))) |ET| |BS|41:A11 142:I01.880.604 537:G05.360.340.024.340.375 1308:D10.212.302.380.410|ES| 2:1 7:1 9:1 19:1 94:1 115:1 221:1 403:1 1620:1 1664:1 5261:1 5262:1 5263:1 5264:1 5265:1

1 	|BT| (S (NP (NP (DT These) (NN animal)) (NP (VP (VP (VBN reduced)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (JJR <) (CD 0.05))) (-RRB- -RRB-))) (NP (JJ colonic) (NN RFC1) (NN mRNA)))) (VP (VBD exhibited) (NP (JJ 2-fold) (NN reduction) (NN plasma) (NN S-adenosylmethionine/S-adenosylhomocysteine)))) |ET| |BS|19:B01.050 46:A03.556.124.526.356 111:D13.444.735.544 175:J01.897.280.500.269 232:D02.886.030.676.180 657:A12.207.152.693|ES| 10:1 14:1 19:1 46:1 311:1 312:1 325:1 370:1 452:1 609:1 677:1 792:1 2400:1 3549:1 3849:1 5266:1 5267:1

1 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (S (NP (NN resveratrol)) (VP (VBP prevent) (NP (NP (NN formation) (NN growth) (JJ colorectal) (NN tumor)) (VP (VBG downregulating) (NP (NNP Kras) (NN expression))))))))) |ET| |BS|20:G03.495 45:G07.700.320.249 388:G05.360.340.024.340.375.500.791.550 1031:C04.588.274.476.411.307|ES| 7:1 17:1 19:1 43:1 102:1 115:1 733:1 792:1 793:1 1479:1 1712:1 2065:1 5142:1

1 	|BT| (S (NP (DT These)) (VP (VBP result) (SBAR (S (NP (VBN demonstrated) (NNS SK-Hep1-NIS)) (VP (MD could) (VP (ADVP (RB selectively)) (VBN killed) (NP (JJ induced) (NN 131I) (NN 188Re-perrhenate) (NN accumulation) (NN NIS) (NN gene) (NN expression)))))))) |ET| |BS|155:G05.355.310 1443:I01.198.240.470|ES| 9:1 19:1 101:1 115:1 412:1 792:1 908:1 1175:1 2120:1 3523:1 5268:1 5269:1 5270:1 5271:1 5272:1

1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VB establish) (SBAR (S (NP (JJ mechanistic) (NN rationale) (NN Src) (NN inhibition) (NN dasatinib) (JJ therapeutic) (NN target) (NN treatment) (JJ pancreatic) (NN cancer)) (VP (VBP identify) (NP (JJ potential) (NNS biomarkers) (NN resistance) (NN Src) (NN inhibition)))))))) |ET| |BS|43:F01.145.544 52:E02 158:D23.101 1386:D02.886.675.184|ES| 18:1 19:1 101:1 103:1 160:1 220:1 467:1 541:1 546:1 792:1 827:1 832:1 1094:1 1269:1 1495:1 1890:1 3674:1 5017:1

1 	|BT| (S (NP (DT These)) (VP (VBP result) (SBAR (S (NP (VBP suggest) (NN alteration) (NN TSLC) (NN cascade)) (VP (MD might) (NP (NN role) (NN hepatocarcinogenesis)) (S (VP (VBG using) (NP (NNP DEN) (NN rat))))))))) |ET| |BS|15:F01.829.316.616 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 19:1 31:1 101:1 350:1 792:1 796:1 798:1 849:1 900:1 951:1 1875:1 5273:1 5274:1

1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN SGE)) (VP (VBZ suppresses) (NP (NN induction) (NN Cyp1a1)) (, ,) (S (VP (VBG leading) (SBAR (S (NP (NN inhibition) (NN ROS) (NN generation)) (ADVP (RB consequently)) (VP (VBD inhibited) (NP (NN hepatocarcinogenesis)) (, ,) (NP (ADVP (RB probably)) (NP (JJ due) (NN suppression) (NN Ahr) (NN activity)))))))))))))) |ET| |BS|43:F01.145.544 86:D01.268.556.435 122:C14.280.383 506:F01.829.263.315 1352:D08.244.453.040.332|ES| 2:1 19:1 101:1 103:1 365:1 399:1 639:1 686:1 736:1 792:1 796:1 900:1 1787:1 2356:1 2453:1 2851:1 4415:1 5160:1 5162:1 5275:1 5276:1

1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBN suggested) (SBAR (S (NP (JJ gestational) (JJ arsenic) (NN exposure)) (VP (VBZ induces) (SBAR (S (NP (NP (JJ tumor-augmenting) (NN change)) (, ,) (PP (VBG including) (NP (NP (JJ oxidative) (NN stress) (NN L1) (NN activation)) (, ,) (NP (JJ late-onset) (NN manner)) (, ,)))) (VP (MD would) (VP (ADVP (RB particularly)) (VB promote) (NP (JJ tumorigenic) (NN expansion) (NN cell) (NN C61A) (NN Ha-ras) (NN mutation)))))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 41:A11 216:Z01.107.084.900.425 716:G03.495.710 1158:D01.268.513.249 1266:G08.686.785.760.769 1444:N05.715.350.075.100|ES| 2:1 19:1 34:1 94:1 101:1 200:1 214:1 225:1 561:1 679:1 747:1 792:1 866:1 925:1 1362:1 1668:1 1809:1 1953:1 2380:1 2522:1 2583:1 3473:1 3976:1 4106:1 5277:1 5278:1 5279:1

1 	|BT| (S (NP (DT This) (JJ toxicogenomic) (NN analysis)) (VP (VBD revealed) (NP (NP (JJ several) (JJ aberrant) (NN gene) (NN expression) (NN change)) (VP (VBN associated) (NP (JJ transplacental) (JJ arsenic) (NN carcinogenesis)))))) |ET| |BS|33:C04.697.098 155:G05.355.310 1158:D01.268.513.249|ES| 9:1 19:1 115:1 169:1 200:1 207:1 262:1 275:1 661:1 807:1 1725:1 4106:1 5280:1 5281:1

1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (CD 1,25) (NN D) (NN VDR)) (VP (VBP regulate) (NP (NN c-MYC/MXD1) (NN network)) (VP (VBP suppress) (NP (NN c-MYC) (NN function)) (, ,) (S (VP (VBG providing) (NP (JJ molecular) (NN basis) (NN cancer) (JJ preventive) (NN action) (NN vitamin) (NN D))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 588:I01.880.853.500.600 720:D04.808.247.222.474 721:D04.808.812.768|ES| 2:1 18:1 19:1 33:1 161:1 625:1 858:1 1140:1 1691:1 1883:1 2013:1 2154:1 2441:1 2591:1 2592:1 3025:1 4529:1 5129:1 5282:1

1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (JJ final) (NN death) (NN outcome) (JJ 5-FU-treated) (NN p53)) (: -) (: /) (: -) (NP (NP (NN cell) (VBD demonstrated) (ADJP (ADJP (JJ caspase-dependent)) (, ,) (ADJP (JJ due) (JJ slow))) (NN pace)) (, ,) (NP (NN accumulation) (JJ mitochondrial) (JJ reactive) (NN oxygen) (NN specie))) (VP (VBZ contributes) (NP (JJ necrotic) (NN characteristic)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 52:E02 134:G04.299.139 135:C23.550.260 560:D03.383.742.698.875.404 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 636:D01.339.431 1216:C23.550.717 1367:D08.811.277.656.262.500.126 1445:D08.811.277.656.300.760.353|ES| 2:1 19:1 94:1 336:1 411:1 547:1 845:1 1175:1 1505:1 1691:1 2004:1 2120:1 2353:1 2354:1 2355:1 2851:1 5283:1 5284:1 5285:1 5286:1 5287:1 5288:1

1 	|BT| (NP (NP (NP (NP (NNP Thymidylate) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN TS)) (-RRB- -RRB-))) (NP (NP (NP (NN overexpression) (JJ key) (NN determinant) (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NN resistance) (JJ human) (NN cancer) (NN cell))))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862|ES| 10:1 14:1 18:1 19:1 36:1 66:1 94:1 152:1 159:1 509:1 1094:1 2307:1 2308:1 3081:1 4359:1

1 	|BT| (S (S (VP (TO To) (VP (VB examine) (NP (NP (JJ possible) (JJ direct) (JJ transcriptional) (NN regulation)) (NP (NN rat) (NN Bcl-2) (NN beta-catenin/Tcf)))))) (, ,) (VP (VBN cloned) (VP (VBN characterized) (SBAR (S (NP (JJ corresponding) (NN promoter) (NN region)) (VP (VBD found) (NP (NP (ADJP (CD 70.1) (NN %)) (NN similarity) (JJ human) (NN counterpart)) (, ,) (NP (NN BCL2))))))))) |ET| |BS|23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 196:G02.111.570.080.689.675 209:G02.111.087.847 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 301:A11.251.353|ES| 2:1 19:1 36:1 37:1 83:1 158:1 369:1 438:1 559:1 667:1 828:1 849:1 960:1 985:1 1048:1 1359:1 1891:1 3526:1 4231:1 4999:1 5289:1 5290:1 5291:1

1 	|BT| (S (VP (ADVP (RB Together)) (, ,) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NN silibinin)) (VP (VBZ inhibits) (NP (NP (NN growth) (NN SW480) (NN tumor)) (VP (VBG carrying) (NP (JJ mutant) (NN APC) (NN gene) (NN down-regulating) (NN CDK8) (NN beta-catenin) (NN signaling)))) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD could) (NP (JJ effective) (NN agent) (NN CRC))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 247:G01.374.676.530 351:A17.360|ES| 2:1 7:1 9:1 11:1 19:1 60:1 102:1 195:1 218:1 245:1 615:1 728:1 796:1 811:1 850:1 908:1 927:1 1639:1 2635:1 3095:1 3096:1 3097:1 3098:1

1 	|BT| (S (NP (NN TOPflash) (NN luciferase) (NN reporter) (NN assay)) (VP (VBD showed) (S (NP (NP (JJ transcriptional) (NN activity) (NN T-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TCF)) (-RRB- -RRB-))) (ADJP (: /) (SBAR (S (NP (JJ lymphoid) (NN enhancer) (NN factor) (-LRB- -LRB-) (NN LEF) (-RRB- -RRB-)) (VP (VBD reduced) (SBAR (S (NP (NP (NN NDRG2) (NN introduction)) (, ,) (NP (NN introduction) (JJ mutant) (NN NDRG2))) (VP (VBD generated) (NP (NN deletion) (JJ site-directed) (NN mutagenesis)))))))))))) |ET| |BS|106:E05.091 209:G02.111.087.847 306:G05.355.600.800 1375:D08.811.682.517 1446:A11.118.637.555.567 1447:E05.393.420.601.575|ES| 2:1 10:1 14:1 19:1 73:1 132:1 185:1 288:1 310:1 399:1 452:1 559:1 811:1 972:1 1059:1 4864:1 4952:1 4963:1 5210:1 5292:1 5293:1 5294:1 5295:1 5296:1 5297:1

1 	|BT| (S (NP (NN Toxaphene)) (VP (VBD induced) (NP (NP (JJ significant) (NP (NP (NN increase) (NN expression) (JJ constitutive) (NN androstane) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN CAR)) (-RRB- -RRB-))) (NN target) (NN gene)) (PRN (-LRB- -LRB-) (NP (NP (NN Cyp2b10)) (, ,) (NP (NN Cyp3a11))) (-RRB- -RRB-))) (NP (QP (CD 32) (CD 320)) (NN ppm) (NN toxaphene)))) |ET| |BS|6:G05.360.340.024.340 1149:D02.455.526.439.913|ES| 2:1 9:1 10:1 14:1 19:1 40:1 115:1 135:1 160:1 186:1 412:1 421:1 604:1 605:1 2546:1 3233:1 3985:1 4164:1 4299:1 5298:1 5299:1

1 	|BT| (S (NP (NN Treatment) (NN HepG2) (NN cell) (NN APAP)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NN expression) (NN DAX-1) (JJ concentration-dependent) (NN manner)))) |ET| |BS|52:E02 661:D02.065.199.092.040 905:F02.830.104.214 1015:A11.251.860.180.432|ES| 19:1 94:1 115:1 124:1 452:1 1668:1 3106:1 3481:1 4193:1 4537:1 5300:1

1 	|BT| (NP (NP (NN Treatment) (NP (NP (NN rat) (NN DHEA) (NN influence) (NN expression) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN P450)) (-RRB- -RRB-))) (NN gene)) (, ,) (FRAG (VBG including) (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN alpha)) (-LRB- -LRB-) (NP (NP (NP (NP (NN PPAR) (NN alpha) (-RRB- -RRB-)) (: -) (NP (NP (NN pregnane) (NN X) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN PXR)) (-RRB- -RRB-)))) (: -) (NP (VBN mediated) (NN induction) (NNS CYP4As) (NN CYP3A23)) (, ,) (NP (NN suppression) (NN CYP2C11)))))) |ET| |BS|6:G05.360.340.024.340 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 536:D12.776.826.239.500 740:D04.808.054.079.429.625 1079:D08.244.453 1448:D08.244.453.450|ES| 2:1 9:1 10:1 14:1 19:1 115:1 186:1 561:1 736:1 849:1 867:1 929:1 1801:1 1836:1 1887:1 2453:1 2549:1 2633:1 2691:1 3106:1 3227:1 3788:1 4048:1 4899:1 5301:1 5302:1 5303:1 5304:1

1 	|BT| (S (NP (NN Treatment) (NN cell) (NN oxazepam) (CD 48) (NN h)) (ADVP (RB also)) (VP (VBD resulted) (SBAR (S (NP (VBN decreased) (NN Tsc-22)) (VP (VBD increased) (NP (NN Gadd45b) (NN expression))))))) |ET| |BS|41:A11 52:E02 179:D01.248.497.300.459.700 1329:D03.438.079.080.070.663|ES| 5:1 19:1 47:1 94:1 115:1 202:1 594:1 3106:1 4741:1 4855:1 5180:1 5305:1 5306:1

1 	|BT| (S (NP (NN Treatment) (NN 5-AzaC)) (ADVP (RB concomitantly)) (NP (VBN upregulated) (NN expression) (NN miR-9-3) (NN miR-193a)) (, ,) (VP (VBD downregulated) (NP (JJ respective) (NN target) (NN gene) (NN NF-kappaB) (NN Mcl-1)))) |ET| |BS|6:G05.360.340.024.340 52:E02 210:D12.776.260.600|ES| 2:1 9:1 19:1 115:1 125:1 160:1 426:1 714:1 3106:1 5307:1 5308:1 5309:1 5310:1 5311:1 5312:1

1 	|BT| (S (NP (NN Troglitazone)) (VP (VBZ induces) (NP (JJ p27Kip1-associated) (NP (JJ cell-cycle) (NN arrest) (JJ down-regulating) (NN Skp2) (JJ human) (NN hepatoma) (NN cell))))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 338:D12.644.360.225.600 351:A17.360 507:D12.776.157.743 515:C04.588.274.623 773:G04.299.134.109|ES| 19:1 36:1 94:1 214:1 602:1 1785:1 3097:1 3116:1 3896:1 5313:1 5314:1

1 	|BT| (S (NP (NN Troglitazone)) (ADVP (RB potently)) (VP (VBD inhibited) (SBAR (S (NP (NN proteasome) (NN activity)) (VP (VBD decreased) (NP (NN Skp2) (NN protein) (NN level))))))) |ET| |BS|122:C14.280.383 507:D12.776.157.743 1281:D05.500.562.500|ES| 4:1 19:1 202:1 249:1 365:1 399:1 1785:1 3116:1 3128:1 4559:1

1 	|BT| (S (NP (NN TS)) (ADVP (RB also)) (VP (ADVP (RB acutely)) (VBN up-regulated) (NP (NP (NN 5-FU) (NN treatment)) (, ,) (, ,) (ADVP (RB thus)) (, ,) (NP (NP (JJ novel) (NN strategy)) (VP (VBG targeting) (NP (NN TS) (NN down-regulation))))) (VP (VBP seem) (NP (JJ promising) (NN term) (VBG modulating) (NN 5-FU) (NN resistance))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 85:G02.111.087.225 142:I01.880.604 150:Z01.542.248.960 154:Z01.058.266.887 259:D12.776.395.240.150.500 560:D03.383.742.698.875.404 849:G08.686.785.760.769.490.500|ES| 2:1 5:1 19:1 257:1 509:1 546:1 616:1 891:1 995:1 1094:1 1114:1 1301:1 1334:1 1517:1 2308:1 2435:1 5315:1 5316:1

1 	|BT| (NP (NP (NP (NN Upregulation) (NN B-cell) (NN translocation) (NN gene) (CD 2) (JJ epigallocatechin-3-gallate)) (PP (IN via) (NP (NN p38) (NN ERK) (NN signaling) (NN block) (NN cell) (NN proliferation) (JJ human) (JJ oral) (JJ squamous) (NN cell) (NN carcinoma) (NN cell))))) |ET| |BS|6:G05.360.340.024.340 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 122:C14.280.383 183:G04.299.233.750 249:G05.355.315.800 310:A11.063.438 339:G02.111.087.880 463:C23.550.210.870 929:C04.557.470.200.400|ES| 9:1 19:1 36:1 94:1 148:1 195:1 299:1 304:1 596:1 742:1 1067:1 1618:1 1666:1 2199:1 2629:1 5047:1 5317:1 5318:1

1 	|BT| (S (NP (JJ Ursodeoxycholic) (NN acid)) (VP (VBZ inhibits) (NP (NP (NN Ras) (NN mutation)) (, ,) (NP (NP (JJ wild-type) (NN Ras)) (NN activation)) (, ,) (NP (NN cyclooxygenase-2) (NN expression) (NN colon) (NN cancer))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 24:D08.811.600.720.750 122:C14.280.383 737:D04.808.105.225.272.962|ES| 2:1 8:1 18:1 19:1 34:1 61:1 113:1 115:1 225:1 615:1 1275:1 1775:1 3121:1

1 	|BT| (S (S (VP (VBG Using) (NP (NN xenograft) (ADJP (NN tumor) (NN model) (JJ severe)) (JJ combined) (JJ immune) (NN deficiency) (NN mouse)))) (, ,) (VP (MD could) (VP (VB show) (SBAR (S (NP (NP (JJ experimental) (JJ systemic) (NN hypergastrinemia)) (VP (VBD induced) (NP (NN administration) (NN omeprazole)))) (VP (VBD led) (NP (VBN enhanced) (NN apoptosis)) (ADVP (RB well)) (NP (NP (JJ marked) (NN increase) (NN IEX-1) (NN expression) (NN Colo320wt) (NN tumor)) (, ,) (NP (NN Colo320mut) (NN tumor))))))))) |ET| |BS|8:C04 39:G04.299.139.160 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 984:D02.886.640.074.500 1449:B01.050.150.900.649.865.635.505.500.550.780|ES| 2:1 7:1 19:1 40:1 52:1 72:1 89:1 115:1 164:1 253:1 263:1 265:1 385:1 412:1 429:1 760:1 787:1 908:1 1719:1 2228:1 2575:1 2802:1 3169:1 3467:1 4693:1 5037:1 5044:1 5319:1 5320:1

1 	|BT| (S (S (VP (VBG Using) (NP (JJ several) (JJ experimental) (NN approach)))) (, ,) (VP (VBP conclude) (SBAR (S (NP (JJ RNA-rather) (JJ DNA-related) (NN stress)) (VP (VBZ follows) (NP (NP (NN caspase) (NN activation)) (RRC (ADVP (RB irrespectively)) (NP (NN p53) (NN status))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 198:D13.444.308 557:D02.241.081.069.600.150 1367:D08.811.277.656.262.500.126 1422:D13.444.735|ES| 2:1 12:1 19:1 225:1 262:1 263:1 416:1 911:1 1719:1 1968:1 2522:1 4796:1 5321:1 5322:1 5323:1 5324:1

1 	|BT| (S (NP (NN UV) (NN exposure)) (VP (VBP result) (NP (NP (NP (JJ ligand-independent) (NN activation) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (JJ subsequent) (NN activation)) (JJ mitogen-activated) (NN protein) (NN kinase) (NN phosphatidylinositol) (NN 3-kinase/Akt) (NN pathway)) (VP (VBG leading) (NP (JJ transcriptional) (NN activation) (NN COX-2) (NN gene)))))) |ET| |BS|6:G05.360.340.024.340 64:D08.811.913.696.620.682.725.400.009.300 86:D01.268.556.435 170:D27.720.470.480 209:G02.111.087.847 249:G05.355.315.800 264:G05.355.315.800 378:D08.811.913.696.620.682.700.755 478:D08.811.913.696.620.682.700.567 1377:D08.811.913.696.620.500.100 1450:G01.358.500.505.650.891 1451:Z01.058.290.190.245|ES| 4:1 9:1 19:1 76:1 101:1 102:1 184:1 185:1 186:1 225:1 383:1 470:1 559:1 639:1 1319:1 1953:1 2081:1 3295:1 4969:1 5325:1 5326:1

1 	|BT| (S (NP (NN Vitamin) (NN D)) (VP (VBZ Enhances) (NP (NNP Efficacy) (NNP Irinotecan) (JJ miR-627-Mediated) (NN Inhibition) (NNP Intratumoral) (NNP Drug) (NNP Metabolism)))) |ET| |BS|43:F01.145.544 67:D26 720:D04.808.247.222.474 721:D04.808.812.768 898:G03.495|ES| 19:1 2345:1 2592:1 2703:1 3665:1 4953:1 5327:1 5328:1 5329:1 5330:1 5331:1

1 	|BT| (S (NP (NN Vitamin) (NN D) (NN signaling)) (VP (VBP suppress) (NP (NP (NN expression) (NN gene) (VBN regulated) (NN c-MYC)) (, ,) (NP (NP (NP (NN transcription) (NN factor) (NN control)) (JJ epidermal) (NN differentiation) (NN cell) (NN proliferation)) (SBAR (WHNP (WP$ whose) (NN activity)) (S (VP (ADVP (RB frequently)) (JJ elevated) (NP (NN cancer))))))))) |ET| |BS|69:G02.111.087.800 74:G04.299.151 142:I01.880.604 155:G05.355.310 166:D12.776.930 183:G04.299.233.750 720:D04.808.247.222.474 721:D04.808.812.768 1095:A10.272.497|ES| 2:1 9:1 18:1 19:1 94:1 115:1 184:1 185:1 195:1 215:1 289:1 299:1 399:1 487:1 625:1 698:1 756:1 919:1 1664:1 2441:1 2592:1 3665:1

1 	|BT| (S (NP (NN Vitamin) (NN E) (NN succinate)) (VP (VBZ induces) (NP (NN NAG-1) (NN expression) (NN p38) (JJ kinase-dependent) (NN mechanism)))) |ET| |BS|469:D08.811.913.696 1452:D03.383.663.283.909.750.249|ES| 19:1 115:1 162:1 214:1 1662:1 1666:1 1667:1 2085:1 3665:1 5332:1

1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD observed) (SBAR (S (NP (NN flavokawain) (NN B)) (VP (VBD caused) (NP (NP (NP (NN G2/M) (NN phase) (NN arrest) (JJ mediated) (NN reduction) (NN level) (NN cyclin) (NN A)) (, ,) (NP (NN cyclin) (NN B1))) (, ,) (NP (NN Cdc2) (NN Cdc25C) (NN increase) (NN p21/WAF1)) (, ,) (NP (NN Wee1) (NN p53) (NN level)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 122:C14.280.383 979:D12.644.360.262.120.100 1431:D12.644.360.262.100 1453:G04.299.134.500.340|ES| 2:1 5:1 12:1 19:1 40:1 69:1 249:1 261:1 370:1 437:1 602:1 743:1 763:1 843:1 2506:1 2528:1 2529:1 3455:1 5333:1 5334:1 5335:1 5336:1 5337:1

1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD demonstrated) (S (NP (NP (NN FOXM1)) (PRN (-LRB- -LRB-) (NP (NN 1B) (NN 1C) (NNS isoforms)) (-RRB- -RRB-))) (ADVP (RB directly)) (VP (VBP bind) (ADVP (RB transcriptionally)) (VP (VBZ regulates) (NP (NP (NP (NN eEF2K) (NN gene) (NN expression) (NN chromatin) (NN immunoprecipitation)) (PRN (-LRB- -LRB-) (NP (NN ChIP)) (-RRB- -RRB-))) (NN luciferase) (NN gene) (NN reporter) (NN assay))))))) |ET| |BS|6:G05.360.340.024.340 106:E05.091 155:G05.355.310 238:D12.776.800 1375:D08.811.682.517 1454:E05.393.170|ES| 5:1 9:1 10:1 14:1 19:1 115:1 288:1 310:1 603:1 621:1 821:1 843:1 1175:1 1346:1 1854:1 4857:1 4963:1 5100:1 5338:1 5339:1 5340:1 5341:1 5342:1

1 	|BT| (S (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD found) (SBAR (S (NP (NN pectolinarigenin)) (ADVP (RB significantly)) (VP (VBD suppressed) (NP (NN osteosarcoma) (NN cell) (NN proliferation))))))) (, ,) (VP (VBD induced) (NP (NP (NP (NP (NP (NN apoptosis)) (VP (VBN reduced) (NP (NN level) (NN STAT3) (JJ downstream) (NN protein) (NN cyclin) (NN D1)))) (, ,) (NP (NN Survivin)) (, ,)) (NP (NP (NN B-cell) (NN lymphoma) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN Bcl-2)) (-RRB- -RRB-)))) (, ,) (NP (NP (NP (NN B-cell) (NN lymphoma) (NN extra-large)) (PRN (-LRB- -LRB-) (NP (NN Bcl-xl)) (-RRB- -RRB-))) (NP (NP (JJ myeloid) (NN cell) (NN leukemia) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN Mcl-1)) (-RRB- -RRB-))))))) |ET| |BS|39:G04.299.139.160 41:A11 82:D12.644.360.024.342.300 183:G04.299.233.750 215:D12.644.360.262.150.100 361:C04.557.337 447:C04.557.450.565.575.650 1424:C04.557.386.480.150 1455:A11.148.378.590 1456:C04.557.337.539 1457:A11.627|ES| 2:1 4:1 5:1 10:1 14:1 19:1 37:1 89:1 94:1 98:1 124:1 148:1 158:1 249:1 251:1 299:1 307:1 412:1 452:1 560:1 591:1 743:1 744:1 843:1 1562:1 2199:1 2785:1 3779:1 5187:1 5312:1 5343:1 5344:1 5345:1

1 	|BT| (FRAG (NP (PRP We)) (VBD characterized) (SBAR (S (NP (NP (NN effect) (JJ gefitinib) (NN EGFR)) (, ,) (NP (NN HER2)) (, ,) (NP (NN ErbB-3) (NN phosphorylation) (NN Western) (NN blot))) (VP (VBD determined) (NP (NN effect) (JJ downstream) (NN signaling) (NN growth))))) (, ,) (NP (NP (NN survival)) (, ,) (NP (NN stress) (NN pathway) (NN effect) (NN proliferation)) (, ,) (NP (NN cell) (NN cycle)) (, ,) (NP (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 45:G07.700.320.249 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 96:I03.784 255:E05.196.401.143 256:E05.196.401.143 353:G04.299.134 972:G02.111.087.677 1350:G05.360.340.024.340.375.500.791.295|ES| 2:1 19:1 75:1 89:1 94:1 102:1 187:1 188:1 195:1 274:1 299:1 383:1 560:1 601:1 843:1 872:1 873:1 985:1 1582:1 2522:1 3310:1 3426:1 4818:1

1 	|BT| (S (NP (PRP We)) (VP (VBD found) (NP (NP (NP (CD 7) (RB differentially) (VBN expressed) (NN gene)) (, ,) (NP (NN cyclin) (NN D1))) (, ,) (NP (NP (NN cyclin) (NN E)) (, ,) (NP (NN c-myc)) (, ,) (NP (NN Fosl1)) (, ,) (NP (NN c-fos)) (, ,) (NP (NN Cd44) (NN follistatin)) (, ,) (NP (NP (VBN known) (NN target) (NN beta-catenin)) (CC and/or) (NP (NN ra))) (NP (NN pathway)))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 6:G05.360.340.024.340 23:D12.776.091.249 165:G05.360.340.024.340.375.500.791.330 215:D12.644.360.262.150.100 1366:D12.776.260.108.765 1458:D12.644.360.262.180 1459:D12.776.157.247|ES| 2:1 6:1 9:1 19:1 37:1 60:1 149:1 160:1 383:1 455:1 556:1 562:1 743:1 744:1 843:1 988:1 1115:1 1139:1 2085:1 5346:1 5347:1 5348:1

1 	|BT| (S (NP (PRP We)) (VP (VBD found) (NP (NP (NN Tsc-22) (NN downregulation) (NN liver) (NN B6C3F1) (NN mouse)) (PP (VBG following) (NP (NP (NN treatment) (CD 2) (NN week)) (NP (NP (NP (JJ carcinogenic) (NNS dos) (JJ antianxiety) (NN drug) (NN oxazepam)) (PRN (-LRB- -LRB-) (NP (CD 2500) (NN ppm)) (-RRB- -RRB-))) (NP (NP (NP (NN peroxisome) (NN proliferator) (NN Wyeth-14,643)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN ppm)) (-RRB- -RRB-))) (NP (NP (CD two) (NN carcinogen) (NN o-nitrotoluene) (NN methyleugenol) (CD three) (NNS noncarcinogens)) (PP (VBG including) (NP (NP (NN p-nitrotoluene)) (, ,) (NP (NN eugenol)) (, ,) (NP (NN acetaminophen)))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 85:G02.111.087.225 242:A03.620 279:D27.888.569.100 661:D02.065.199.092.040 912:D27.888.569.100.675 1165:D02.241.223.200.054.500 1329:D03.438.079.080.070.663 1460:D27.505.696.277.950.015|ES| 2:1 10:1 14:1 19:1 37:1 52:1 148:1 191:1 482:1 546:1 561:1 595:1 783:1 836:1 843:1 933:1 1887:1 1888:1 2125:1 2412:1 2653:1 3233:1 3346:1 3510:1 3986:1 4023:1 4293:1 4417:1 4741:1 5180:1 5349:1 5350:1 5351:1 5352:1 5353:1 5354:1

1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (S (NP (NN TCE)) (VP (VBD decreased) (SBAR (S (NP (NN methylation) (NN c-jun) (NN c-myc) (NN gene)) (VP (VBD increased) (NP (NN level) (NNS mRNAs)))))))))) |ET| |BS|36:G02.111.087.029.538 111:D13.444.735.544 186:G05.360.340.024.340.375.500.791.420|ES| 9:1 19:1 47:1 81:1 202:1 249:1 447:1 455:1 843:1 993:1 1527:1 5355:1 5356:1

1 	|BT| (S (NP (PRP We)) (VP (VBD hypothesized) (SBAR (S (NP (JJ novel) (NN class) (NN oligoamine) (NN analogue)) (VP (MD would) (VP (ADVP (RB effectively)) (VB inhibit) (NP (NN LSD1)) (RB thus) (VP (VBP cause) (S (NP (NN reexpression)) (VP (ADVP (RB aberrantly)) (NP (VBN silenced) (NN gene))))))))))) |ET| |BS|6:G05.360.340.024.340 122:C14.280.383 259:D12.776.395.240.150.500|ES| 9:1 19:1 843:1 866:1 891:1 1334:1 1370:1 1380:1 1750:1 1779:1 2656:1 2657:1 2658:1 2814:1 2977:1 5062:1 5357:1

1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NN function) (NN vitamin) (JJ D-regulated) (NN miR-627) (JJ intratumoral) (NN CYP3A4) (NN suppression) (NN role)) (VP (VBG enhancing) (NP (NN efficacy) (NN chemotherapy)))))) |ET| |BS|15:F01.829.316.616 142:I01.880.604 151:E02.319 720:D04.808.247.222.474 721:D04.808.812.768 1348:D08.244.453.400|ES| 19:1 31:1 33:1 403:1 495:1 843:1 2304:1 2453:1 2527:1 2591:1 4804:1 4805:1 5358:1 5359:1

1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (JJ anti-glioblastoma) (NN response) (NN celecoxib)) (JJ p53-dependent) (, ,) (SBAR (IN whether) (FRAG (NP (NP (ADJP (NN celecoxib) (VBD induced)) (NN DNA) (NN damage)) (VP (VBG leading) (NP (JJ p53-dependent) (NN G1) (NN cell) (NN cycle) (NN arrest)))))) (, ,) (VP (VBD followed) (NP (JJ autophagy) (NN apoptosis))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 86:D01.268.556.435 390:G04.299.139.399 526:G05.355.180 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 2:1 19:1 88:1 89:1 94:1 221:1 403:1 412:1 494:1 601:1 602:1 639:1 666:1 670:1 843:1 1317:1 1848:1 2807:1 3130:1 5360:1

1 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (NP (ADJP (NP (NN induction) (NN G)) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (: -)) (NN S-phase) (NN arrest) (JJ caspase-mediated) (NN apoptosis)) (NP (JJ androgen-dependent) (NP (JJ human) (NN LNCaP) (NN cell)))) (, ,) (S (VP (VBP express) (NP (JJ wild-type) (NN p53))) (, ,) (NP (JJ androgen-independent) (, ,) (NP (JJ p53-mutant) (NN DU145) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 892:D27.505.696.399.472.161 1367:D08.811.277.656.262.500.126|ES| 2:1 8:1 10:1 12:1 14:1 19:1 36:1 89:1 94:1 98:1 208:1 261:1 602:1 736:1 843:1 2691:1 3423:1 3520:1 4880:1 4904:1 4905:1 4925:1 5099:1 5361:1

1 	|BT| (S (NP (PRP We)) (VP (VBP provide) (NP (NN evidence) (NN HDACi) (NN treatment) (NN lead) (JJ potent) (JJ transcriptional) (NN repression) (NN TS) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 52:E02 86:D01.268.556.435 154:Z01.058.266.887 208:F01.393.821 209:G02.111.087.847|ES| 9:1 19:1 22:1 38:1 254:1 505:1 509:1 546:1 559:1 706:1 711:1 843:1

1 	|BT| (S (NP (PRP We)) (VP (VBP show) (ADVP (RB herein)) (NP (NN induction) (NP (NP (NN tumor) (NN suppressor) (NN gene) (JJ COOH-terminal) (NN Src) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN Csk)) (-RRB- -RRB-))) (NN NSAID) (JJ important) (JJ antiproliferative) (RB hence) (JJ chemopreventive) (NN effect)))) |ET| |BS|206:G05.360.340.024.340.375.249 469:D08.811.913.696 487:G05.355.315.800 624:D27.505.696.706.018 796:D27.505.696.663.850.014.040.500|ES| 7:1 9:1 10:1 14:1 19:1 75:1 429:1 470:1 700:1 736:1 843:1 902:1 1736:1 1946:1 3120:1 3674:1 4230:1 4499:1 5362:1 5363:1

1 	|BT| (S (NP (PRP We)) (VP (VBP show) (SBAR (S (NP (JJ individual) (JJ homozygous) (JJ minor) (NN ODC) (NN A-allele)) (VP (VBD reported) (S (VP (VBG using) (NP (NN aspirin)) (NP (NP (QP (RB approximately) (CD 0.10)) (NN time)) (NP (NP (JJ likely) (NN adenoma) (NN recurrence) (JJ non-aspirin) (NN user)) (NP (JJ homozygous) (JJ major) (NN G-allele))))))))))) |ET| |BS|12:Z01.542.049 17:C04.557.470.035 30:Z01.058.290.190.800 31:D08.811.520.224.800 77:G05.360.340.024.340.030 322:G01.910 493:M01 496:C23.550.291.937 670:D02.455.426.559.389.657.410.595.176 1108:M01.416 1283:G05.380.554 1461:E05.318.740.600|ES| 19:1 42:1 350:1 429:1 462:1 843:1 993:1 1081:1 1328:1 1843:1 2487:1 2512:1 2697:1 3881:1 4564:1 5364:1 5365:1 5366:1 5367:1 5368:1 5369:1

1 	|BT| (S (NP (PRP We)) (VP (VBD showed) (SBAR (S (ADJP (RB previously) (JJ S-trans)) (, ,) (NP (NP (JJ trans-farnesylthiosalicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FTS)) (-RRB- -RRB-))) (VP (VBZ disrupts) (SBAR (S (NP (NN Ras) (NN membrane) (NN anchorage) (NN disturbance)) (VP (VBZ contributes) (NP (NN inhibition) (NN cell) (NN transformation) (NN tumor) (NN growth)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 45:G07.700.320.249 1344:A10.615|ES| 2:1 7:1 10:1 14:1 19:1 94:1 102:1 103:1 132:1 843:1 845:1 1275:1 1384:1 1527:1 1775:1 3622:1 4549:1 4551:1 5253:1 5370:1 5371:1 5372:1

1 	|BT| (NP (NP (NP (NN YGK)) (NP (ADVP (RB significantly)) (VBD repressed) (NP (NN E6/E7) (NN oncogene) (JJ transcriptional) (NN level)) (, ,) (NP (NP (JJ subsequent) (NN reactivation) (NN p53) (NN p21) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 9:G05.360.340.024.340.375.500 208:F01.393.821 209:G02.111.087.847|ES| 2:1 10:1 12:1 14:1 19:1 24:1 115:1 124:1 249:1 311:1 312:1 315:1 466:1 559:1 1135:1 1319:1 1913:1 5373:1 5374:1

-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN exposure) (NN cell) (NN Japonicone) (NN A)) (VP (VBD caused) (NP (NN inactivation) (NN TNF-alpha-TAK1-IKK-NF-kappaB) (NN axis) (NN inhibition) (JJ TNF-alpha-stimulated) (NN NF-kappaB) (NN activity) (JJ nuclear) (NN translocation)))) (, ,) (VP (VBD followed) (NP (NP (NN downregulation) (NN NF-kappaB) (NN target) (NN gene)) (VP (VBN involved) (NP (NP (NP (NN cell) (NN apoptosis)) (PRN (-LRB- -LRB-) (NP (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (NN XIAP)) (, ,) (NP (NN TRAF2))) (-RRB- -RRB-))) (NP (NP (NN cell) (NN cycle) (NN growth)) (PRN (-LRB- -LRB-) (NP (NN cyclin) (NN D)) (, ,) (NP (NN c-Myc)) (-RRB- -RRB-)))))))) |ET| |BS|6:G05.360.340.024.340 39:G04.299.139.160 41:A11 43:F01.145.544 45:G07.700.320.249 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 210:D12.776.260.600 353:G04.299.134 463:C23.550.210.870 579:A02.835.232.834.151.383 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1046:D12.644.360.262.150 1522:D12.644.360.024.500.750|ES| 2:1 9:1 10:1 14:1 19:1 69:1 89:1 94:1 102:1 103:1 158:1 160:1 334:1 399:1 595:1 601:1 714:1 743:1 774:1 824:1 1256:1 1314:1 1618:1 1953:1 2089:1 2506:1 2592:1 3130:1 4814:1 5646:1 5647:1 5648:1 5649:1 5650:1

-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN hesperidin) (NN administration)) (VP (VBD restored) (SBAR (S (NP (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (NN activity) (NN turn)) (VP (VBD prevented) (NP (NN accumulation) (NNS oncoproteins)) (NP (NP (NN beta-catenin)) (, ,) (NP (NN c-jun) (NN c-myc)))))))) |ET| |BS|23:D12.776.091.249 584:D12.776.624.664 1477:D03.383.663.283.266.450.252.500|ES| 2:1 10:1 14:1 19:1 60:1 66:1 92:1 334:1 399:1 455:1 1944:1 1972:1 2120:1 2575:1 3652:1 3653:1 4893:1 5356:1 5651:1 5652:1 5653:1

-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (PP (IN upon) (NP (NN TQ) (NN treatment))) (, ,) (NP (NN beta-catenin)) (VP (VP (VBD retained) (SBAR (S (NP (NN membrane) (NN c-myc)) (VP (VBD decreased) (NP (NN nucleus)))))) (, ,) (S (VP (VBN associated) (NP (VBN reduced) (NN cell) (NN proliferation) (NN villus)))))) |ET| |BS|23:D12.776.091.249 52:E02 183:G04.299.233.750 1104:A11.284.430.106 1344:A10.615|ES| 2:1 19:1 60:1 94:1 169:1 202:1 299:1 334:1 452:1 455:1 460:1 546:1 1577:1 1951:1 3622:1 3873:1 5654:1

-1 	|BT| (FRAG (ADVP (RB Here)) (, ,) (NP (NP (NN report) (ADJP (RB inversely) (JJ related)) (NN expression) (NN miR-137) (NN CAR) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell)) (, ,) (SBAR (WHADVP (WRB wherein)) (S (NP (NN miR-137)) (VP (VBD downregulated) (NP (JJ resistant) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320 139:J01.937.500.100|ES| 2:1 19:1 94:1 115:1 400:1 417:1 418:1 419:1 420:1 421:1 422:1 423:1 424:1 425:1 426:1 427:1

-1 	|BT| (S (ADVP (RB However)) (, ,) (VP (VBZ remains) (ADJP (JJ unknown) (SBAR (IN whether) (S (NP (NP (NN neoplasia)) (VP (VBN associated) (NP (NNP Pten) (ADJP (NN loss) (JJ dependent)) (JJ upstream) (NN IGF) (NN ligand) (NN supply) (FW vivo))))))))) |ET| |BS|8:C04 170:D27.720.470.480 581:D12.644.276.937|ES| 2:1 19:1 32:1 169:1 221:1 321:1 378:1 433:1 442:1 640:1 1835:1 1996:1 2182:1 3728:1 5655:1 5656:1

-1 	|BT| (S (ADVP (RB However)) (, ,) (NP (JJ combined) (NN effect) (NN mda-7) (NN sulindac)) (ADVP (RB previously)) (VP (VBN tested))) |ET| |BS|251:D02.455.426.559.847.486.875|ES| 2:1 19:1 75:1 164:1 433:1 869:1 1527:1 2988:1 5657:1

-1 	|BT| (S (NP (NN Hypermethylation) (NN miR-137) (NN promoter) (JJ negative) (NN regulation) (NN miR-137) (NN CAR)) (VP (VP (VBP contribute) (NP (NP (NN part)) (VP (VBD reduced) (NP (NN miR-137) (NN expression))))) (VP (VBD increased) (NP (NN CAR) (NN MDR1) (NN expression) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 142:I01.880.604|ES| 19:1 47:1 83:1 94:1 115:1 420:1 421:1 423:1 424:1 438:1 448:1 449:1 450:1 451:1 452:1 453:1

-1 	|BT| (NP (NP (NP (NN Immunohistochemistry) (NN beta-catenin)) (, ,) (NP (NN c-myc)) (, ,) (NP (NP (NN Ki-67) (NN TUNEL-staining)) (VP (VBN performed) (VP (VBP investigate) (NP (NP (NN TQ) (POS 's)) (NN effect) (JJ major) (JJ colorectal) (NN cancer) (NN pathway))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 143:E01.370.225.500.607.512 144:E05.393.475|ES| 2:1 17:1 18:1 19:1 60:1 75:1 383:1 454:1 455:1 456:1 457:1 458:1 459:1 460:1 461:1 462:1

-1 	|BT| (FRAG (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN ERK5) (NN inhibition)) (VP (VBD increased) (NP (NP (NN response) (NN HCT116) (NN p53)) (CC +) (NP (: /) (CC +) (NN cell) (NN 5-FU)))) (, ,)) (VBD failed) (VB sensitize) (NP (NP (NN HCT116) (NN p53)) (: -)) (: /) (: -) (NP (NP (NN cell) (JJ cytotoxic) (NN effect) (JJ chemotherapeutic) (NN agent)) (, ,) (VP (VBG suggesting) (NP (NP (JJ p53-dependent) (NN axis)) (VP (VBG mediating) (NP (NN 5-FU) (NN sensitization))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 560:D03.383.742.698.875.404 579:A02.835.232.834.151.383 660:D27.505.954.248 717:A11.251.210.190.380|ES| 2:1 19:1 47:1 75:1 88:1 94:1 103:1 244:1 468:1 494:1 566:1 728:1 761:1 1009:1 1457:1 1505:1 1762:1 2089:1 2308:1 5471:1 5658:1 5659:1 5660:1 5661:1

-1 	|BT| (S (PP (IN In) (NP (JJ intestinal) (JJ epithelial) (NN cell) (NN IEC-6) (NN colon) (NN cancer) (NN cell) (NN HCT-116))) (, ,) (NP (NN IL-6) (NN expression) (NN signaling)) (VP (VBN assessed) (NP (NP (NNP SHH) (NN inhibitor) (NN level) (JJ inflammatory) (NN mediator)) (, ,) (NP (NP (NN proliferation)) (, ,) (NP (NN apoptosis)) (, ,) (NP (NN tumorsphere) (NN formation))) (, ,) (NP (NP (NN tumorigenesis)) (VP (ADVP (RB also)) (VBN measured)))))) |ET| |BS|20:G03.495 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 47:A03.556.124 69:G02.111.087.800 75:A11.436 201:D12.644.276.374.465.224 228:E05.978 1523:E01.370.225.625.400 1524:E04.936.225.687.500|ES| 2:1 5:1 18:1 19:1 43:1 78:1 89:1 94:1 109:1 113:1 115:1 127:1 195:1 244:1 249:1 299:1 380:1 738:1 789:1 2430:1 3148:1 3351:1 3823:1 5662:1 5663:1 5664:1

